^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    AR-V7 positive

    Apply
    Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 (STARVE-PC) (NCT02601014)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Completed
    Last update posted :
    02/03/2022
    Initiation :
    03/15/2016
    Primary completion :
    12/03/2020
    Completion :
    10/06/2021
    AR
    |
    AR expression • AR-V7 expression • AR-V7 positive • AR splice variant 7 • AR-V7 negative • AR splice variant 7 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • enzalutamide capsule • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)